Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第10页

Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer. 图卡替尼联合曲妥珠单抗与帕妥珠单抗联合曲妥珠单抗治疗化疗难治性、her2阳性、RAS野生型不可切除或转移性结直肠癌的成本-效果分析

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-09 DOI: 10.1080/14737167.2026.2642646

Mengmeng Liu, Lu Zhong, Mei Dong, Tong Liu

{"title":"Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.","authors":"Mengmeng Liu, Lu Zhong, Mei Dong, Tong Liu","doi":"10.1080/14737167.2026.2642646","DOIUrl":"10.1080/14737167.2026.2642646","url":null,"abstract":"Background: This study evaluates the cost-effectiveness of tucatinib plus trastuzumab compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (CRC) from the perspective of healthcare payers in China.Research design and methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab.Results: When the price of tucatinib was based on that of lapatinib in China, the estimated cost for tucatinib plus trastuzumab was higher than that of pertuzumab plus trastuzumab (29,130.32 USD vs 12,160.58 USD). The estimated utility was also greater compared to that of pertuzumab plus trastuzumab (2.07 QALYs vs 1.07 QALYs). The ICER was calculated at 17,075.25 USD/QALY, suggesting the tucatinib plus trastuzumab treatment was cost-effective compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC at a WTP threshold of 40,000 USD/ QALY.Conclusions: Tucatinib plus trastuzumab was cost-effective if its price was the same as lapatinib for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC from the perspective of healthcare payers in China. Our exploratory result could provide a reference for clinical application of tucatinib plus trastuzumab when they are correctly interpreted.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"537-547"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden Tree - a conceptual framework for the burden associated with pediatric infectious diseases: a Delphi approach. 负担树-与儿童传染病相关的负担的概念框架：德尔菲方法。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-04-05 DOI: 10.1080/14737167.2026.2650164

Cristina Carias, Danielle Riley, Amanda L Eiden, Ashley L Enstone, Isabelle J Whittle, Deanna B Marshall, Charlotte W Oswald, J Mick Tilford

{"title":"Burden Tree - a conceptual framework for the burden associated with pediatric infectious diseases: a Delphi approach.","authors":"Cristina Carias, Danielle Riley, Amanda L Eiden, Ashley L Enstone, Isabelle J Whittle, Deanna B Marshall, Charlotte W Oswald, J Mick Tilford","doi":"10.1080/14737167.2026.2650164","DOIUrl":"10.1080/14737167.2026.2650164","url":null,"abstract":"Background: Accurate economic evaluations require capturing the full value of health interventions, yet broader impacts are often inconsistently represented. This study developed and validated the 'Burden Tree'- a conceptual framework to comprehensively capture the burden of pediatric infectious diseases on patients and families.Methods: A double-blind modified-Delphi panel was conducted with 21 experts from the US and Europe in pediatric infectious diseases. The process, informed by targeted literature review and expert input, involved two rounds of online surveys and a virtual consensus meeting to elicit and validate categories, elements, and sub-elements of the Burden Tree.Results: Burden Tree categories included direct medical and non-medical costs, productivity losses, and impact on quality of life, each differentiating elements before, during, and after the episode. Validated sub-elements covered costs related to hospitalizations, drugs, visits, tests, healthcare transport, caregiver bereavement or exhaustion; housing modifications, special accommodations and resources for sequelae; caregiver and patient absenteeism and presenteeism, caregiver employment termination; caregiver and patient changes in health-related quality of life, and discrimination following the episode. The panel agreed the Burden Tree categories were comprehensive, mutually exclusive, and customizable.Conclusion: This modified-Delphi panel validated a comprehensive and mutually exclusive framework for economic evaluation inclusion.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"511-522"},"PeriodicalIF":2.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concerns on methodological assumptions in the health economic evaluation of return-to-work interventions. 对重返工作岗位干预措施的健康经济评价中方法假设的关注。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-02-18 DOI: 10.1080/14737167.2026.2629352

Afschin Gandjour

{"title":"Concerns on methodological assumptions in the health economic evaluation of return-to-work interventions.","authors":"Afschin Gandjour","doi":"10.1080/14737167.2026.2629352","DOIUrl":"10.1080/14737167.2026.2629352","url":null,"abstract":"Introduction: High sickness absence and disability claims create major societal and budget pressures, making return-to-work (RTW) interventions a central policy priority. Because decisions often hinge on whether productivity gains are counted, robust long-horizon economic models are influential - but also vulnerable to strong extrapolation assumptions.Areas covered: This Key Paper Evaluation examines a recent modeling study of RTWinterventions comparing a 3½-week inpatient multimodal occupational rehabilitation (I-MORE) with outpatient Acceptance and Commitment Therapy (ACT). The authors link a randomized trial to 7 years of registry follow-up and project costs and effects over a 25-year horizon from healthcare and societal perspectives.Expert commentary: The analysis is transparent and well executed, but the study's headline finding - lifetime dominance of I-MORE when productivity is counted - hinges on structural assumptions that effectively extend a 3½-week inpatient program into persistent productivity gains over a 25-year horizon: transition intensities are frozen beyond 4 years, and within-state absence-day differences are held constant thereafter, generating persistent productivity gains even after state prevalences converge. Health-related quality of life is observed only to 14 months and then modeled as state-specific constants, compressing incremental quality-adjusted life years and leaving the healthcare-only incremental cost-effectiveness ratio unfavorable. We argue that lifetime savings should be treated as upper-bound estimates and that decision relevance would be strengthened by waning-effect scenarios, mid-term horizons, and tests of the absorbing disability state. We also highlight the need for diagnosis-by-treatment analyses and stepped-care sequences given the heterogeneous population and fixed-dose ACT comparator.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"313-316"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain. 西班牙偏头痛急性治疗中瑞米坦和拉西米坦相关不良事件的成本。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-01-12 DOI: 10.1080/14737167.2026.2615680

Sonia Santos-Lasaosa, Beatriz Armada, Carlota Moya-Alarcón, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Pablo Irimia

{"title":"Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.","authors":"Sonia Santos-Lasaosa, Beatriz Armada, Carlota Moya-Alarcón, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Pablo Irimia","doi":"10.1080/14737167.2026.2615680","DOIUrl":"10.1080/14737167.2026.2615680","url":null,"abstract":"Objective: To compare the cost of adverse events (AEs) associated with the acute treatment with rimegepant (RIM) versus lasmiditan (LAS) for migraine in Spain.Methods: A probabilistic modeling analysis was performed, using second-order Monte Carlo simulations, from the perspective of the Spanish National Health System (SNHS). The cost per patient of all AEs described with RIM or LAS in 12 clinical trials, obtained through a systematic review, was analyzed. Several sensitivity analyzes (among them, a matching adjusted indirect comparison -MAIC- of the two long-term studies) were also performed. The cost of AEs management (€ 2024) was obtained from Spanish sources.Results: The probabilistic model estimated that RIM compared to LAS would generate savings of €612.79 (95% CI €159.49-1339.43) per treated patient with migraine, in a treatment period of 6.11 ± 3.25 months, €98.54 per month. In the MAIC analysis, a saving per patient of €697.04 (95% CI: €514.44-879.04) was obtained in a treatment period of 12.4 months. The probability of RIM saving in all analysis was 100%.Conclusions: In accordance with this model, the favorable safety profile of RIM compared to LAS would generate savings for the SNHS in health-care resources in all the scenarios considered.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"361-368"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers' submissions and a comparison between manufacturers and Canada's Drug Agency (CDA) analyses. 2018年至2025年加拿大肿瘤药物卫生技术评估报告：对制造商提交的方法批评以及制造商与加拿大药品管理局（CDA）分析之间的比较

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-02-19 DOI: 10.1080/14737167.2026.2632265

Sepideh Mardani Jadid, Mobina Dokhaei, Naeemeh Dini, Masoud Tajadod, Dorsa Azizi Khezri, Kimia Hariri, Mitchell Levine, Fatemeh Mirzayeh Fashami

{"title":"Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers' submissions and a comparison between manufacturers and Canada's Drug Agency (CDA) analyses.","authors":"Sepideh Mardani Jadid, Mobina Dokhaei, Naeemeh Dini, Masoud Tajadod, Dorsa Azizi Khezri, Kimia Hariri, Mitchell Levine, Fatemeh Mirzayeh Fashami","doi":"10.1080/14737167.2026.2632265","DOIUrl":"10.1080/14737167.2026.2632265","url":null,"abstract":"Objective: Providing an analytical framework to evaluate critiques by Canada's Drug Agency (CDA) and to compare the manufacturers' economic analyses versus CDA's reanalyses for oncology medications.Methods: We reviewed CDA oncology reports from 2018 to 2025. Clinical data and methodological critiques were compared between submissions receiving positive versus negative recommendations.Results: Positive recommendations were significantly more frequent in submissions that included randomized trials (90.1% vs. 61.9%), trials with a control arm (90.8% vs. 65.4%), and trials incorporating phase III or phase IV evidence (79.6% vs. 41.9%) (p < 0.001). Although CDA was generally receptive to indirect treatment comparisons (ITC), studies using naïve ITC (73.0% for naïve ITC vs. 88.1% for others, p = 0.031) or matching-adjusted indirect comparison (MAIC) (75.0% for MAIC vs. 91.2% for other ITCs, p = 0.009) had significantly lower rates of positive recommendations. When comparing submissions with positive versus negative recommendations, certain critiques were significantly more frequent in the latter. These included not having enough evidence available (82.2% vs. 100%, p = 0.011), and using surrogate outcomes (23.9% vs. 51.6%, p = 0.002).Conclusion: Using MAIC or naïve ITC, submitting a dossier that includes limited clinical evidence, and surrogate outcomes are associated with a negative recommendation.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"451-463"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024-2033. 2024-2033年捷克共和国早期免疫疗法对健康和工作生产力的影响。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 DOI: 10.1080/14737167.2026.2634755

Gittan Blezer, Karl Patterson, Tomáš MIčoch, Jana Alahakoon, Yizhen Lai, Vivek Khurana, Raquel Aguiar-Ibáñez

{"title":"Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024-2033.","authors":"Gittan Blezer, Karl Patterson, Tomáš MIčoch, Jana Alahakoon, Yizhen Lai, Vivek Khurana, Raquel Aguiar-Ibáñez","doi":"10.1080/14737167.2026.2634755","DOIUrl":"10.1080/14737167.2026.2634755","url":null,"abstract":"Background: This study evaluated the health and productivity impact of expanding the use of inhibitors of programmed cell death protein 1 (PD-1) or its ligand (PD-L1), referred to as anti-PD-(L)1 agents, to early-stage cancer treatment in the Czech Republic.Research design and methods: A four-state Markov-based model compared the use of anti-PD-(L)1 agents for early-stage disease (ESD) treatment of melanoma (stage IIB-C and III), renal cell carcinoma (RCC), and triple-negative breast cancer (TNBC) versus the established use of anti-PD-(L)1 agents only for metastatic disease in the Czech Republic from 2024-2033. Outcomes included recurrence-/event-/disease-free life-years (LYs), total LYs, quality-adjusted LYs (QALYs), productive work years, events/recurrences, metastatic disease treatments, and deaths.Results: Of 16,410 eligible patients, 13,745 initiated ESD treatment with anti-PD-(L)1 agents. ESD treatment was estimated to increase recurrence-/event-/disease-free LYs (+10.6%), QALYs (+4.1%), and productive years for both patients (+22.1%) and caregivers (+21.0%), while decreasing events/recurrences (-22.2%), metastatic treatments (-17.6%), and total deaths (-23.2%).Conclusions: Expanding the use of anti-PD-(L)1 agents for early-stage cancer treatment in the Czech Republic is expected to reduce events/recurrences and metastatic treatments while also extending survival, quality-of-life, and productive work years, supporting the clinical and societal value of earlier use of innovative immunotherapies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"429-441"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147276158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation. ixekizumab， tofacitinib和golimumab治疗银屑病关节炎的比较成本效用分析：一个真实世界的马尔可夫模型模拟。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-02-09 DOI: 10.1080/14737167.2026.2629351

Rubén Queiro, Ignacio Braña, Paula Alvarez, Marta Loredo, Estefanía Pardo, Stefanie Burger

{"title":"Comparative cost-utility analysis of ixekizumab, tofacitinib, and golimumab in psoriatic arthritis: a real-world Markov model simulation.","authors":"Rubén Queiro, Ignacio Braña, Paula Alvarez, Marta Loredo, Estefanía Pardo, Stefanie Burger","doi":"10.1080/14737167.2026.2629351","DOIUrl":"10.1080/14737167.2026.2629351","url":null,"abstract":"Background: Psoriatic arthritis (PsA) requires long-term, phenotype-oriented management. This study compared the cost-utility of ixekizumab, tofacitinib, and golimumab using a real-world modeling approach.Research design and methods: A 10-year Markov model was developed from the perspective of the Spanish National Health System, informed by three real-world PsA cohorts. Transition probabilities were derived from drug-persistence data. Utilities and direct medical costs were obtained from published sources. Approved dosing, standard treatment durations, and annual cycles were modeled. Main outcomes included total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). Scenario analyses evaluated a 20% price reduction and phenotype-specific settings (enthesitis, dactylitis, axial PsA, refractory disease, prior TNFi failure, and relevant comorbidity).Results: All three agents were cost-effective in the base case, with ICERs below the €30,000/QALY threshold. Ixekizumab provided the highest QALYs and was most cost-effective in axial PsA, enthesitis, and refractory disease. Tofacitinib, with the lowest total cost, was dominant in TNFi-failure scenarios. Golimumab offered the best value in dactylitis and comorbid patients and showed marked improvement under reduced-price conditions. Safety-related discontinuations were infrequent across cohorts.Conclusions: Ixekizumab, tofacitinib, and golimumab are all cost-effective options for PsA. These findings support phenotype-guided therapeutic decisions and highlight the influence of drug pricing.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"419-427"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing, updating and validating DepMod 2.0: an R-based decision-analytic model for the cost-effectiveness of depression interventions. 开发、更新和验证DepMod 2.0：一个基于r的抑郁症干预成本效益决策分析模型。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-03-03 DOI: 10.1080/14737167.2026.2634764

Stijn B Peeters, Frederick W Thielen, Ben F M Wijnen

{"title":"Developing, updating and validating DepMod 2.0: an R-based decision-analytic model for the cost-effectiveness of depression interventions.","authors":"Stijn B Peeters, Frederick W Thielen, Ben F M Wijnen","doi":"10.1080/14737167.2026.2634764","DOIUrl":"10.1080/14737167.2026.2634764","url":null,"abstract":"Background: Depression imposes a substantial clinical and economic burden, and evaluating the cost-effectiveness of prevention and treatment strategies is essential for informed mental health policy. The original DepMod model was developed to support such evaluations, but evolving evidence and modeling standards have created the need for an updated version.Research design and methods: This study introduces DepMod 2.0, an updated health-economic Markov model for depression. The model was recalibrated using recent epidemiological data on incidence, prevalence, population size, and severity distribution. In addition, DepMod was transitioned from an Excel-based implementation to an open-source R package, providing both a stand-alone R function and an interactive Shiny interface. Model validation includes assessment using the TECH-VER checklist, validation against population-level reference parameters, and comparison with outcomes from the original DepMod model.Results: DepMod 2.0 produced outcomes consistent with published reference values and the original model, supporting its technical validity. Differences observed in prevention scenarios, were attributable to updated epidemiological inputs, including higher prevalence and a greater proportion of severe cases.Conclusions: DepMod 2.0 is an updated and validated R-based model that supports economic evaluation of depression prevention and treatment strategies across diverse healthcare settings.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"443-450"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147343921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic and humanistic burden of chronic liver diseases in the United States. 美国慢性肝病的经济和人文负担

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-02-25 DOI: 10.1080/14737167.2026.2634760

Javeria Khalid, Yinan Huang, Rajender R Aparasu

{"title":"Economic and humanistic burden of chronic liver diseases in the United States.","authors":"Javeria Khalid, Yinan Huang, Rajender R Aparasu","doi":"10.1080/14737167.2026.2634760","DOIUrl":"10.1080/14737167.2026.2634760","url":null,"abstract":"Background: Little is known about the healthcare burden of Chronic liver disease (CLD) post-introduction of newer antiviral therapies for hepatitis. Therefore, this national study examined healthcare expenditures, productivity loss, and health-related quality of life (HRQoL) of patients with CLD.Methods: This retrospective, cross-sectional analysis utilized the 2014-2021 Medical Expenditure Panel Survey involving patients with CLD ≥18 years. Two-part model was employed to estimate incremental direct medical costs. Multivariable models were used to evaluate missed workdays and HRQoL.Results: Annually, 1.63 million patients (95%CI=1.47-1.81) were diagnosed with CLD, with a prevalence of 0.59%. The mean annual incremental healthcare expenditure attributable to CLD was $11,711 (95%CI=$6,867.048-$16,555.36). Patients with CLD have 0.12 (95%CI=0.09-0.15) more missed workdays, translating into a national productivity loss of $51.6 million. Additionally, HRQoL was significantly lower in CLD patients, with mean differences of -3.72 (95%CI = -4.6 to -2.84) for physical component summary score and -1.83 (95%CI = -2.68 to -0.97) fore mental component summary score.Conclusions: CLD was associated with a significant healthcare burden, as evidenced by healthcare expenditure, productivity loss, and HRQoL. Therefore, concerted efforts are needed to improve the prevention and management of CLD to reduce the disease burden.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"379-387"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic evaluation of percutaneous patent foramen ovale closure versus medical therapy in patients with a cryptogenic stroke: a systematic review. 经皮卵圆孔未闭封闭与药物治疗对隐源性卒中患者的经济评价：一项系统综述。

IF 2.2 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-02-18 DOI: 10.1080/14737167.2026.2626572

Aziz Rezapour, Mohsen Rezaeian, Saeed Bagheri Faradonbeh, Mohammad Barzegar, Ali Zareh Askari, Hamid Pourasghari, Mohammad Mehdi Peighambari, Aghdas Souresrafil

{"title":"Economic evaluation of percutaneous patent foramen ovale closure versus medical therapy in patients with a cryptogenic stroke: a systematic review.","authors":"Aziz Rezapour, Mohsen Rezaeian, Saeed Bagheri Faradonbeh, Mohammad Barzegar, Ali Zareh Askari, Hamid Pourasghari, Mohammad Mehdi Peighambari, Aghdas Souresrafil","doi":"10.1080/14737167.2026.2626572","DOIUrl":"10.1080/14737167.2026.2626572","url":null,"abstract":"Introduction: A patent foramen ovale (PFO) closure reduces the risk of recurrent cryptogenic ischemic strokes in young to middle-aged patients. We aimed to review the studies on the cost-effectiveness of percutaneous closure of a PFO in comparison to medical therapy in the prevention of cryptogenic strokes in patients with a PFO.Methods: This systematic review searched PubMed, EMBASE, Web of Science, Cochrane, and Scopus from 1990 to 2025.Results: Twelve articles qualified for inclusion. Closed PFOs resulted in a quality-of-life gain of 3.25 to 4.55 years for most countries. According to the study, the incremental cost-effectiveness ratio per year of life gained was between $3,882.54 and $248,590. Percutaneous closure of the PFO has been found to be cost-effective compared to medical therapy in most countries, with the exception of Argentina.Conclusions: On the basis of the results of the present study, percutaneous closure of the PFO was cost-effective compared to medical therapy in preventing a cryptogenic stroke in patients with a PFO. A majority of studies were conducted in countries with high incomes. Further studies on the cost-effectiveness of percutaneous closure of the PFO are required in low- and middle-income countries.Registration: PROSPERO (CRD42024544835).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"339-349"},"PeriodicalIF":2.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0